Raportul
Știri verificate despre finanțări, sedii centrale și leadership de la cele mai inovatoare companii din lume
356 rapoarte și mai multe
Sciensus Appoints James Tugendhat Chief Executive Officer
Sciensus has appointed James Tugendhat OBE, most recently Group CEO of HC-One, as Chief Executive Officer, taking over from interim CEO Gordon Cox.
Microbiotica Raises £36M Series C for Oral Microbiome Medicines
Microbiotica announced the first close of a £36 million ($48 million) Series C led by British Business Bank to advance MB310 into Phase 2 clinical development in ulcerative colitis.
OMass Therapeutics Raises $310M Series C for Small-Molecule Therapeutics
OMass Therapeutics raised an oversubscribed $310 million Series C co-led by Bain Capital Life Sciences, Forbion and Novo Holdings to advance its small molecule pipeline in endocrinology and immunology.
Harmony Biosciences Appoints Peter Anastasiou President and Chief Executive Officer
Harmony Biosciences appointed Chief Operating Officer Peter Anastasiou as CEO effective January 1, 2027, succeeding retiring CEO Jeffrey M. Dayno, to lead the company’s next phase of growth.
Oxide Raises $445M Series D for On-Premises Cloud Computers
Oxide raised a $445 million Series D led by Eclipse to secure components, increase manufacturing, and serve customers of its on-premises cloud computer.
TETRAPHARM Appoints Rolf Sass Sørensen Chief Executive Officer
TETRAPHARM appointed Rolf Sass Sørensen, formerly of Bavarian Nordic, as CEO to succeed co-founder Martin Rose and lead the Danish biopharmaceutical company’s continued development.
Parallel Systems Raises $100M Series C for Autonomous Freight Rail
Parallel Systems closed a $100 million Series C led by AVP to scale production of its Panther rail vehicle and expand into international markets.
KymaThera Raises $80M Series B for Selective PI3Kα Inhibitor
KymaThera raised an $80 million Series B led by Alta Partners to advance K-1728, an oral PI3Kα inhibitor for cancer and vascular malformations.
Breye Therapeutics Raises €67.5M Series A for Oral Retinal Disease Drugs
Breye Therapeutics raised an over-subscribed €67.5 million Series A co-led by Mission BioCapital and Novo Holdings to advance danegaptide into a Phase 2 trial.
Afișare 9 rapoarte • Pagina 1 • Categorie: all
Rămâneți înaintea pieței
Primiți perspective săptămânale în inbox. Fără spam, doar inteligență.